OncoMatch/Clinical Trials/NCT07195682
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Is NCT07195682 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BMS-986506 for renal cell carcinoma.
Treatment: BMS-986506 — This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immunotherapy
at least two different treatment plans in the past, including immunotherapy and a targeted therapy
Must have received: targeted therapy
at least two different treatment plans in the past, including immunotherapy and a targeted therapy
Must have received: anti-PD-1 therapy
at least one standard treatment plan that included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the other)
Must have received: anti-PD-L1 therapy
at least one standard treatment plan that included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the other)
Must have received: VEGFR inhibitor
at least one standard treatment plan that included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the other)
Cannot have received: HIF2A inhibitor
prior treatment with HIF2a inhibitors
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0006 · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
- Local Institution - 0002 · Philadelphia, Pennsylvania
- SCRI Oncology Partners · Nashville, Tennessee
- START San Antonio · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify